现场 扬子晚报网2月3日讯(通讯员王誉橙黄为民记者万凌云姜天圣)1月30日至2月1日，经过由中国合格评定国家认可委员会(CNAS)委派的五位国家级权威专家 连续三天的严格评审，扬中市人医检验科成功通过ISO15189医学实验室认可的现场评审。这标志着扬中市人医检验科在质量与能力建设上取得重大阶段 性成果，向获得全球公认的医学实验室"金标准"认可迈出了最关键的一步。 现场 现场 据悉，本次现场评审专家组阵容强大，由山东大学齐鲁第二医院公衍文主任担任组长，成员涵盖中国人民解放军总医院张有江主任、四川省人民医院传良 敏主任、东部战区总医院时永辉主任和南京市第一医院何帮顺主任，五位专家均为医学检验领域的权威人士，确保了评审工作的专业性、严谨性和公正 性。 此次现场评审，被业内称为对医学实验室的"终极体检"，评审过程全面、系统且严苛。三天时间里，专家组严格依照ISO15189国际标准，通过查阅海量管 理文件、追踪检验原始记录、现场考核实操能力、深度访谈实验室工作人员、走访临床相关科室等多种方式，对扬中市人医检验科的管理体系运行、技术 能力水平进行了全方位、无死角的核查。评审范围覆盖从患者样本接收到检验报告发出的全过程， ...

Core Viewpoint - The article highlights the challenges faced by a private company, Guangxi Yonggui Medical Testing Laboratory Co., Ltd., in establishing a regional medical testing center in Guangxi, which has become a "stalled" project due to various disputes and issues related to government cooperation [1]. Group 1: Project Background - The project involved a total investment of 60 million yuan, with an initial investment of 32 million yuan completed by the company [1]. - The medical testing center obtained its operating license in January 2022 but has not been able to commence operations due to bureaucratic hurdles [4][5]. Group 2: Financial Impact - The company incurs fixed monthly expenses of approximately 300,000 yuan, leading to significant cumulative losses over the four years of stalled operations [5]. - Due to unpaid rent, the company has faced court-enforced actions, resulting in the auction of core medical equipment and the cancellation of its operating license [5]. Group 3: Official Response and Issues - Local authorities indicated that the project was signed under the influence of a former county secretary who is now serving a prison sentence for bribery, highlighting the lack of thorough research and collective decision-making [6]. - The agreement has multiple compliance risks, including conflicts with laws and regulations, risks of state asset loss, and irregular procurement procedures, which are cited as fundamental reasons for the project's failure to proceed [6]. Group 4: Contractual Challenges - The agreement contains unequal terms, including a penalty of 10 million yuan for breach of contract and additional compensation if the company withdraws, creating a dilemma of "no way to proceed, no way to exit" [10]. - A working group has been established to negotiate a resolution, with potential legal proceedings if negotiations fail [10]. Group 5: Broader Implications - The ongoing dispute has resulted in significant losses for private capital and has affected the integration and optimization of medical resources in the county [12]. - The article raises concerns about the procurement processes and potential hidden issues in the establishment of the laboratory, which was once recognized for its high standards in the region [12].

二、分配方案 1.发放年度：2025年前三季度 2.分派对象： 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次利润分配方案经广州金域医学检验集团股份有限公司（以下简称"公司"）2026年1月21日的2026年 第一次临时股东会审议通过。 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任公司上海分公司（以下简 称"中国结算上海分公司"）登记在册的本公司全体股东。 3.分配方案： 本次利润分配以方案实施前的公司总股本463,258,275股为基数，每股派发现金红利0.88元（含税），共 计派发现金红利407,667,282.00元。 三、相关日期 ■ 四、分配实施办法 1.实施办法 除公司自行发放对象外，其余股东的红利委托中国结算上海分公司通过其资金清算系统向股权登记日上 海证券交易所收市后登记在册并在上海证券交易所各会员办理了指定交易的股东派发。已办理指定交易 的投资者可于红利发放日在其指定的证券营业部领取现金红利，未办理指定交易的股东红利暂由中国结 算上海分公司保管，待办理指定交易后再进 ...

证券代码：603882 证券简称：金域医学 公告编号：2026-011 广州金域医学检验集团股份有限公司 2025年前三季度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 每股分配比例 A股每股现金红利0.88元 2.自行发放对象 ● 相关日期 ■ ● 差异化分红送转： 否 一、通过分配方案的股东会届次和日期 本次利润分配方案经广州金域医学检验集团股份有限公司（以下简称"公司"）2026年1月21日的2026年 第一次临时股东会审议通过。 2.分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任公司上海分公司（以下简 称"中国结算上海分公司"）登记在册的本公司全体股东。 3.分配方案： 本次利润分配以方案实施前的公司总股本463,258,275股为基数，每股派发现金红利0.88元（含税），共 计派发现金红利407,667,282.00元。 三、相关日期 1.实施办法 除公司自行发放对象外，其余股东的红利委托中国结算上海分公司通过其资金清算系统向股权登记日上 海证券 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： 1、本期业绩预告的具体适用情形：净利润为负值。 2、广州金域医学检验集团股份有限公司（以下简称"公司"）预计2025年年度实现归属于上市公司股东 的净利润为-13,000万元到-19,000万元，与上年同期相比，将同比减亏19,124.11万元到25,124.11万元。 3、公司预计2025年年度实现归属于上市公司股东的扣除非经常性损益的净利润为-12,000万元到-18,000 万元。 一、本期业绩预告情况 （一）业绩预告期间 2025年1月1日至2025年12月31日。 （二）业绩预告情况 1、经财务部门初步测算，预计2025年年度实现归属于上市公司股东的净利润为-13,000万元到-19,000万 元，与上年同期相比，将同比减亏19,124.11万元到25,124.11万元。 2、公司预计2025年年度实现归属于上市公司股东的扣除非经常性损益的净利润为-12,000万元到-18,000 万元。 （三）本次所预计的业绩未经审计机构审计。 二、上年同期业绩情况 ...

Group 1 - The core viewpoint of the news is that Kingmed Diagnostics experienced a significant drop in stock price, with a decline of 9.37% on January 16, resulting in a trading volume of 1.084 billion yuan [1] - On January 16, Kingmed Diagnostics had a financing buy-in amount of 100 million yuan, with a net financing buy of -14.32 million yuan, indicating a higher level of financing activity compared to the past year [1] - The total financing and securities balance for Kingmed Diagnostics as of January 16 is 530 million yuan, which accounts for 3.53% of its market capitalization, indicating a high financing balance relative to historical levels [1] Group 2 - Kingmed Diagnostics provides a wide range of medical testing services, including nearly 80 types of testing technologies and approximately 3,200 testing projects to over 23,000 medical institutions across China [2] - The company's main business revenue composition includes 91.20% from medical diagnostic services, 6.45% from sales of diagnostics, and smaller contributions from other services [2] - For the period from January to September 2025, Kingmed Diagnostics reported a revenue of 4.538 billion yuan, reflecting a year-on-year decrease of 19.23%, and a net profit attributable to shareholders of -79.6095 million yuan, a decline of 184.84% [2] Group 3 - Since its A-share listing, Kingmed Diagnostics has distributed a total of 2.545 billion yuan in dividends, with 1.647 billion yuan distributed over the past three years [3] - As of September 30, 2025, the top ten circulating shareholders of Kingmed Diagnostics include Hong Kong Central Clearing Limited as the second-largest shareholder, holding 35.5057 million shares, a decrease of 2.8676 million shares from the previous period [3] - The investment fund "Zhaoshang Advantage Enterprise Mixed A" has exited the list of the top ten circulating shareholders [3]

Core Insights - The integration of artificial intelligence in grassroots healthcare is seen as a new pathway to enhance the construction of county-level medical communities and address capability shortcomings [1][2] Group 1: AI Platform Launch - The launch of the AI-assisted diagnostic platform in Fengkai County, Guangdong, marks the establishment of the first county-level AI healthcare platform in the province, aimed at improving access to quality medical resources [1] - The platform will connect 19 county hospitals and township health centers, creating a model for "smart healthcare" that can be quantified, replicated, and promoted across the province and nation [1][2] Group 2: Data Sharing and Integration - The platform focuses on building a "data sharing hub" to connect hospitals and grassroots testing and pathology information systems, enhancing regional medical service capabilities [2] - Gold Domain Medical, as a co-builder of the regional testing and pathology center, is integrating medical data from county and township institutions into a centralized management platform [2] Group 3: AI Applications in Healthcare - The platform will utilize Gold Domain Medical's proprietary AI models and applications to embed intelligent features into hospital workflows, providing clinical doctors with tools for report interpretation, project evaluation, and medication assistance [3] - The integration of AI tools aims to significantly enhance the convenience of diagnosis and treatment processes for healthcare providers [3] Group 4: Strategic Goals and Future Plans - The establishment of the AI-assisted diagnostic platform is a key initiative for Fengkai County to implement the "Healthy China" strategy and the "Hundred Counties, Thousand Towns, and Ten Thousand Villages" project [3] - Future plans include the creation of a "Gold Domain-Fengkai Medical AI Research Training Center" to enhance the understanding and application of AI tools among regional medical personnel [3]

数据宝统计，截至14:37，兰卫医学成交额10.20亿元，创2023年4月13日以来新高。最新股价下跌 1.20%，换手率20.39%。上一交易日该股全天成交额为4.41亿元。 据天眼查APP显示，上海兰卫医学检验所股份有限公司成立于2007年12月24日，注册资本40051.7万人 民币。（数据宝） （文章来源：证券时报网） ...

Core Viewpoint - The company, Guangzhou Kingmed Diagnostics Group Co., Ltd., anticipates a net loss for the fiscal year 2025, primarily due to extended collection periods for accounts receivable leading to significant credit impairment losses [1]. Financial Performance - The company expects the net profit attributable to shareholders for 2025 to be negative, indicating an operational loss for the year [1]. - The final financial data will be disclosed in the official 2025 annual report, which will provide the confirmed figures [1]. Compliance and Disclosure - The company commits to adhering to the Shanghai Stock Exchange listing rules and will expedite its financial accounting processes to release the 2025 annual performance forecast promptly [1]. - Designated media for information disclosure includes China Securities Journal, Shanghai Securities Journal, Securities Times, Securities Daily, and the Shanghai Stock Exchange website [1].

Group 1 - WuXi AppTec (药明康德) is a leading global pharmaceutical R&D outsourcing company with a comprehensive layout in AI healthcare, integrating AI technology throughout the drug development process [1] - The AI drug discovery platform developed by WuXi AppTec utilizes machine learning to analyze vast compound data, significantly shortening the early development cycle of small molecules and biologics [1] - The platform has been applied in new drug development projects for oncology and neurodegenerative diseases [1] Group 2 - Aier Eye Hospital (爱尔眼科) is a leading domestic eye care chain focusing on the intelligent upgrade of the entire eye diagnosis and treatment process through AI [2] - The AI fundus screening system developed by Aier can accurately identify common eye diseases with an accuracy rate exceeding 95%, implemented in over a thousand grassroots eye clinics and health check centers nationwide [2] - The company also utilizes AI technology to create personalized correction plans for myopia patients and enhance the precision and safety of surgeries [2] Group 3 - Kanglong Chemical (康龙化成) is a core player in the domestic pharmaceutical R&D outsourcing sector, leveraging AI technology to enhance R&D service efficiency [3] - The AI drug development platform integrates molecular simulation and machine learning, reducing compound screening cycles from months to weeks [3] - AI is also used to construct disease models and simulate drug metabolism processes, improving data accuracy and reducing animal usage [3] Group 4 - Tigermed (泰格医药) is a leading clinical trial CRO in China, focusing on the intelligent transformation of the entire clinical trial process through AI [4] - The AI clinical trial management system enables intelligent project initiation, patient recruitment, and data management, improving recruitment efficiency by over 30% [4] - AI algorithms are employed for real-time monitoring of clinical trial data, providing precise risk warnings and decision-making support for pharmaceutical companies [4] Group 5 - Kelaiying (凯莱英) is a global leader in the pharmaceutical CDMO sector, applying AI technology to enhance drug production and R&D [5] - AI algorithms are used to design optimal chemical synthesis pathways, reducing production costs and enhancing safety and yield [5] - The company has developed an AI drug R&D platform to predict the physicochemical properties and biological activity of compounds, aiding in the rapid selection of candidate drug molecules [5] Group 6 - Meinian Health (美年健康) is a leading health checkup company in China, with AI healthcare as a core driver for upgrading its services [6] - The AI intelligent health check system covers the entire process from appointment scheduling to health report interpretation, with AI imaging diagnosis achieving accuracy close to that of professional doctors [6] - The company integrates national health check big data to conduct chronic disease trend research, supporting public health decision-making [6] Group 7 - Zhaoyan New Drug (昭衍新药) is a leader in non-clinical safety evaluation of drugs, focusing on the intelligent upgrade of drug safety evaluation through AI [7] - The AI drug safety prediction platform integrates vast toxicology data and machine learning algorithms to predict potential toxicity of new drugs early [7] - AI technology is also used for intelligent monitoring of experimental animals, enhancing data accuracy and reliability [7] Group 8 - BGI Genomics (华大基因) is a leading global player in the field of gene sequencing, deeply integrating AI technology with gene sequencing [8] - AI algorithms are applied to analyze gene sequencing data, significantly improving the efficiency and accuracy of genetic disease diagnosis [8] - The company has developed a big data platform to support precision medicine and drug development through AI analysis of vast genetic data [8] Group 9 - Tongce Medical (通策医疗) is a leading domestic dental care chain focusing on the intelligent upgrade of dental diagnosis and treatment through AI [9] - The AI dental imaging diagnosis system can automatically analyze dental CT and panoramic images, assisting dentists in making accurate diagnoses [9] - The company also utilizes AI technology to optimize patient appointment and triage systems, enhancing patient flow and reducing wait times [9] Group 10 - Haoyuan Pharmaceutical (皓元医药) is a core player in the domestic pharmaceutical reagents and raw materials sector, focusing on intelligent upgrades in drug and reagent development through AI [10] - The AI molecular design platform significantly shortens the discovery cycle of lead compounds in drug development [10] - AI technology is also used to optimize inventory management, reducing costs and improving supply chain efficiency [10] Group 11 - Jiuzhou Pharmaceutical (九洲药业) is an important player in the domestic CDMO sector, focusing on the intelligent upgrade of drug production and R&D through AI [11] - AI algorithms are utilized to design optimal chemical synthesis pathways, enhancing yield and reducing production costs [11] - The company has developed an AI drug R&D platform to predict the biological activity and pharmacokinetic properties of compounds [11] Group 12 - KingMed Diagnostics (金域医学) is a leading third-party medical testing company in China, with AI healthcare applications throughout the testing process [12] - The AI data analysis system can automatically analyze vast testing data, quickly identifying abnormal indicators and generating reports [12] - The company also integrates national testing big data to conduct epidemiological research, supporting public health prevention efforts [12] Group 13 - Dian Diagnostics (迪安诊断) is a leading third-party medical diagnostic service provider, with AI healthcare as a core driver for enhancing diagnostic capabilities [13] - The AI diagnostic platform covers multiple fields, achieving over 90% accuracy in identifying tumor cells and infectious lesions [13] - AI technology is also used to optimize testing processes, improving laboratory throughput and efficiency [13] Group 14 - Chengdu XianDao (成都先导) is a leading new drug development company, deeply integrating AI technology with its core DNA-encoded compound library business [14] - AI algorithms are used to design DNA-encoded compound libraries, significantly improving screening efficiency and hit rates [14] - The company has developed a cloud computing platform for AI drug R&D, providing intelligent services to global pharmaceutical companies [14] Group 15 - Sanbo Brain Science (三博脑科) is a specialized medical service institution in the field of neurosurgery, with AI applications in both healthcare and brain-computer interface technology [15] - The AI neuroimaging diagnosis system can automatically analyze brain CT and MRI images, assisting in diagnosing neurological diseases [15] - The company collaborates with research institutions to conduct clinical studies on brain-computer interfaces, helping patients regain motor function [15] Group 16 - Innovation Medical (创新医疗) is a comprehensive medical service enterprise focusing on intelligent upgrades in rehabilitation and orthopedic diagnosis through AI [16] - The AI rehabilitation assessment system collects patient movement data to automatically evaluate rehabilitation effectiveness and adjust training plans [16] - AI technology is also used to analyze X-ray and CT images for orthopedic diagnosis, enhancing the precision of surgical planning [16]